Frank Sacks

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence
    Michel P Hermans
    Endocrinology and Nutrition Unit, Universite Catholique de Louvain, 10 Avenue Hippocrate, Brussels 1200, Belgium
    Cardiovasc Diabetol 10:20. 2011
  2. ncbi Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses
    Stella Trompet
    Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
    BMC Med Genet 12:131. 2011
  3. ncbi Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake
    F M Sacks
    Department of Nutrition, Harvard School of Public Health, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Hypertension 31:131-8. 1998
  4. ncbi Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins
    Frank M Sacks
    Nutrition Department, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Cardiol 90:165-7. 2002
  5. ncbi Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease
    Carlos O Mendivil
    Harvard School of Public Health, Department of Nutrition, 665 Huntington Avenue, Boston, MA 02115, USA
    Circulation 124:2065-72. 2011
  6. ncbi Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal
    Frank M Sacks
    Harvard School of Public Health, Department of Nutrition, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 88:4525-32. 2003
  7. ncbi Dietary fat, the Mediterranean diet, and health: reports from scientific exchanges, 1998 and 2000. Introduction
    Frank M Sacks
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Med 113:1S-4S. 2002
  8. ncbi Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease
    Frank M Sacks
    Nutrition Department, Harvard School of Public Health, FMS, Boston, Massachusetts 02115, USA
    Am J Med 113:13S-24S. 2002
  9. ncbi Major potential of diet treatment for type 2 diabetes
    Frank M Sacks
    Cardiovascular Disease Prevention, Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Curr Diab Rep 8:249-50. 2008
  10. ncbi After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate
    Frank M Sacks
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Cardiol 102:34L-40L. 2008

Research Grants

  1. Dietary Macronutrients and Weight Loss
    Frank Sacks; Fiscal Year: 2007
  2. Carbohydrate: Amount and Type Affecting Risk for CVD and Diabetes
    Frank M Sacks; Fiscal Year: 2010
  3. Carbohydrate: Amount and Type Affecting Risk for CVD and Diabetes
    Frank Sacks; Fiscal Year: 2009
  4. Carbohydrate: Amount and Type Affecting Risk for CVD and Diabetes
    Frank Sacks; Fiscal Year: 2007
  5. VLDL and LDL Particle Types as CHD Risk Factors
    Frank Sacks; Fiscal Year: 2006
  6. Apo A2, C1 and C2 and Diet in human apoB Metabolism
    Frank Sacks; Fiscal Year: 2005
  7. KINETICS OF HUMAN POSTPRANDIAL LIPOPROTEIN METABOLISM
    Frank Sacks; Fiscal Year: 2001
  8. Dietary Fat and HDL Metabolism
    Frank M Sacks; Fiscal Year: 2010

Collaborators

Detail Information

Publications83

  1. ncbi Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence
    Michel P Hermans
    Endocrinology and Nutrition Unit, Universite Catholique de Louvain, 10 Avenue Hippocrate, Brussels 1200, Belgium
    Cardiovasc Diabetol 10:20. 2011
    ..Non-HDL-C represents a simple surrogate for apoB in hypertriglyceridemic and/or T2DM patients. ApoB and non-HDL-C show high correlation, although the degree of mutual concordance remains debated in CV risk evaluation...
  2. ncbi Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses
    Stella Trompet
    Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
    BMC Med Genet 12:131. 2011
    ..In this report we first describe the rationale of the PROSPER/PHASE project and second show that the PROSPER/PHASE study can be used to study pharmacogenetics in the elderly...
  3. ncbi Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake
    F M Sacks
    Department of Nutrition, Harvard School of Public Health, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Hypertension 31:131-8. 1998
    ..This study strengthens evidence for the importance of potassium for blood pressure regulation in the general population...
  4. ncbi Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins
    Frank M Sacks
    Nutrition Department, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Cardiol 90:165-7. 2002
  5. ncbi Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease
    Carlos O Mendivil
    Harvard School of Public Health, Department of Nutrition, 665 Huntington Avenue, Boston, MA 02115, USA
    Circulation 124:2065-72. 2011
    ..Low-density lipoprotein (LDL) that contains apolipoprotein (apo) C-III makes up only 10% to 20% of plasma LDL but has a markedly altered metabolism and proatherogenic effects on vascular cells...
  6. ncbi Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal
    Frank M Sacks
    Harvard School of Public Health, Department of Nutrition, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 88:4525-32. 2003
  7. ncbi Dietary fat, the Mediterranean diet, and health: reports from scientific exchanges, 1998 and 2000. Introduction
    Frank M Sacks
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Med 113:1S-4S. 2002
  8. ncbi Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease
    Frank M Sacks
    Nutrition Department, Harvard School of Public Health, FMS, Boston, Massachusetts 02115, USA
    Am J Med 113:13S-24S. 2002
    ..It is likely that many diets could be designed that could prevent CVD. This potential diversity is crucial for engaging the diverse cultures and tastes of people worldwide in cardiovascular disease prevention...
  9. ncbi Major potential of diet treatment for type 2 diabetes
    Frank M Sacks
    Cardiovascular Disease Prevention, Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Curr Diab Rep 8:249-50. 2008
  10. ncbi After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate
    Frank M Sacks
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Cardiol 102:34L-40L. 2008
    ..These findings also give impetus to investigate mechanisms by which fenofibrate and peroxisome proliferator-activated receptor-alpha activation may protect the endothelium of small blood vessels in patients with type 2 diabetes...
  11. ncbi Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors
    Frank M Sacks
    Nutrition Department, Harvard School of Public Health F M S, Boston, Mass 02115, USA
    Circulation 105:1424-8. 2002
    ..We conducted exploratory analyses of participant characteristics, lipid risk factors, and risk reduction in this group...
  12. ncbi Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
    F M Sacks
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass, USA
    Circulation 97:1446-52. 1998
    ..Although LDL lowering has been shown to reduce recurrent coronary events in patients with coronary heart disease, little direct information is available on the extent of LDL lowering required to achieve this outcome...
  13. ncbi Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events
    F M Sacks
    Department of Medicine, Harvard Medical School, USA
    Herz 24:51-6. 1999
    ..These findings also raise the possibility that the efficacy of pravastatin may partly result from anti-inflammatory as well as lipid lowering properties...
  14. ncbi VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
    F M Sacks
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Circulation 102:1886-92. 2000
    ..Plasma triglyceride concentration has been an inconsistent independent risk factor for coronary heart disease, perhaps because of the metabolic heterogeneity among VLDL particles, the main carriers of triglycerides in plasma...
  15. ncbi Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project
    F M Sacks
    Brigham and Women s Hospital, Harvard Medical School Boston, MA 02115, USA
    Circulation 102:1893-900. 2000
    ..Previous trials have had insufficient numbers of coronary events to address definitively the effect of lipid-modifying therapy on coronary heart disease in subgroups of patients with varying baseline characteristics...
  16. ncbi Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group
    F M Sacks
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, USA
    N Engl J Med 344:3-10. 2001
    ....
  17. ncbi The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials
    F M Sacks
    Nutrition Department, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Cardiol 88:14N-18N. 2001
    ..Because most coronary events have not been prevented in the statin trials, nonstatin lipid therapy, including fibrates, may be necessary to further reduce the unacceptably high rate of coronary artery disease...
  18. ncbi Metabolic syndrome: epidemiology and consequences
    Frank M Sacks
    Nutrition Department, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115, USA
    J Clin Psychiatry 65:3-12. 2004
    ....
  19. ncbi The apolipoprotein story
    Frank M Sacks
    Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
    Atheroscler Suppl 7:23-7. 2006
    ....
  20. ncbi Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo
    Frank M Sacks
    Harvard School of Public Health and Harvard Medical School, Boston, MA, USA, USA
    J Lipid Res 50:894-907. 2009
    ..Treatment with delipidated plasma tended to reduce diet-induced aortic atherosclerosis in monkeys measured by intravascular ultrasound. These findings link the conversion of small to large HDL, in vivo, to improvement in atherosclerosis...
  21. ncbi LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients
    Sung-Joon Lee
    Department of Nutrition, Harvard School of Public Health, Boston, Mass 02115, USA
    Arterioscler Thromb Vasc Biol 23:853-8. 2003
    ..CONCLUSIONS: LDL with apoCIII strongly predicts coronary events in diabetic patients independently of other lipids and may be an atherogenic remnant of triglyceride-rich VLDL metabolism...
  22. ncbi Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal
    Stephanie E Chiuve
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 89:2207-13. 2004
    ..Methyltestosterone may lower plasma triglycerides through a reduction in apoCIII...
  23. ncbi Characteristics of the diet patterns tested in the optimal macronutrient intake trial to prevent heart disease (OmniHeart): options for a heart-healthy diet
    Janis F Swain
    General Clinical Research Center, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Am Diet Assoc 108:257-65. 2008
    ..To describe the nutrient and food composition of the diets tested in the Optimal Macronutrient Intake Trial to Prevent Heart Disease (OmniHeart)...
  24. ncbi Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease
    Sung-Joon Lee
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Atherosclerosis 167:293-302. 2003
    ..Diabetes status per se does not appear to be associated with high concentrations of apoCIII-containing TG-rich lipoprotein particles, if the plasma TG levels are similar...
  25. ncbi Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men
    Tobias Pischon
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
    Circulation 112:3375-83. 2005
    ....
  26. ncbi Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates
    Frank M Sacks
    Department of Nutrition, Harvard School of Public Health, Boston, USA
    N Engl J Med 360:859-73. 2009
    ..The possible advantage for weight loss of a diet that emphasizes protein, fat, or carbohydrates has not been established, and there are few studies that extend beyond 1 year...
  27. ncbi Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III
    Chunyu Zheng
    Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
    Am J Clin Nutr 88:272-81. 2008
    ..Dietary monounsaturated fat (MUFA) and complex carbohydrates have different effects on triglyceride-rich lipoprotein (TRL) metabolism...
  28. ncbi Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial
    Jeremy D Furtado
    Harvard School of Public Health, Boston, MA, USA
    Am J Clin Nutr 87:1623-30. 2008
    ..Dietary intake affects lipoprotein concentration and composition related to those apolipoproteins...
  29. ncbi Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study
    Eldrin F Lewis
    Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 42:1446-53. 2003
    ..Patients who experience late-onset HF have a 10-fold increased risk of death compared with other MI survivors. Baseline characteristics can risk stratify patients at high risk of subsequent HF...
  30. ncbi A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction
    John D Seeger
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Am J Cardiol 92:1447-51. 2003
    ..Serum low-density lipoprotein levels were reduced by statin therapy, and there were fewer incidents of AMI in statin initiators than in noninitiators...
  31. ncbi A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men
    Simin Liu
    Division of Preventive Medicine, Department of Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital and Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Atherosclerosis 161:469-74. 2002
    ..However, whether this polymorphism is associated with risk of myocardial infarction (MI) is uncertain...
  32. ncbi Food sources of individual plasma phospholipid trans fatty acid isomers: the Cardiovascular Health Study
    Renata Micha
    Division of Cardiovascular Medicine, University of Washington, Seattle, WA, USA
    Am J Clin Nutr 91:883-93. 2010
    ..However, multiple TFA isomers exist, each with potentially different health effects. Different food sources of these specific TFA isomers are not well established...
  33. ncbi Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans
    Chunyu Zheng
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 26:891-6. 2006
    ..CONCLUSIONS: Plasma LpL may act like an apolipoprotein to enhance the clearance of apoB lipoproteins in humans, a mechanism particularly important for intestinal lipoproteins in the postprandial state...
  34. ncbi Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells
    Akio Kawakami
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Circulation 113:691-700. 2006
    ..Thus, we investigated the direct effect of lipoproteins that do or do not have apoCIII, and apoCIII itself, on adhesion of THP-1 cells, a human monocytic cell line, to vascular endothelial cells (ECs)...
  35. ncbi Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
    Sandeep Bansal
    Donald W Reynolds Center for Cardiovascular Research, Brigham and Women s Hospital, Boston, MA 02215, USA
    JAMA 298:309-16. 2007
    ..Although triglyceride levels are typically obtained in the fasting state, postprandial hypertriglyceridemia may play an important role in atherosclerosis...
  36. ncbi Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins
    Carlos O Mendivil
    Harvard School of Public Health, Boston, Mass 02115, USA
    Arterioscler Thromb Vasc Biol 30:239-45. 2010
    ..We aimed to clarify the influence of apolipoprotein C-III (apoCIII) on human apolipoprotein B metabolism...
  37. ncbi Rationale and design of the Optimal Macro-Nutrient Intake Heart Trial to Prevent Heart Disease (OMNI-Heart)
    Vincent J Carey
    Channing Laboratory, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Clin Trials 2:529-37. 2005
    ..Whether partial replacement of some carbohydrate (C) with either protein (P) or unsaturated fat (U) can further improve these and other cardiovascular (CVD) risk factors is unknown...
  38. ncbi Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial
    Jeremy D Furtado
    Harvard School of Public Health, Boston, MA, USA
    Am J Clin Nutr 92:714-22. 2010
    ..In blacks, the concentration of lipoproteins with apo C-III is unknown, and the response to dietary strategies that lower triglyceride and apo C-III has not been investigated..
  39. ncbi Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 28:562-7. 2008
    ..The purpose of this study was to investigate the association between the Ala227Pro polymorphism in the ADAMTS1 metalloproteinase gene and coronary heart disease and benefit from statin therapy in 2 independent cohorts...
  40. ncbi Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control
    Vincent J Carey
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 106:757-63. 2010
    ..Thus, high TGs might have greater importance in patients with optimal rather than greater LDL cholesterol concentrations...
  41. ncbi Alternatives for macronutrient intake and chronic disease: a comparison of the OmniHeart diets with popular diets and with dietary recommendations
    Russell J de Souza
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02215, USA
    Am J Clin Nutr 88:1-11. 2008
    ..The lower carbohydrate diets improved the CVD risk factors. Several popular diets claiming health benefits emphasize carbohydrate, fat, or protein or various combined approaches...
  42. ncbi Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype
    Chunyu Zheng
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Circulation 121:1722-34. 2010
    ..Here, we aim to identify defects of apolipoprotein (apo) B lipoprotein metabolism that characterize hypertriglyceridemia, focusing on apoC-III and apoE...
  43. ncbi Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications
    Stephanie E Chiuve
    Department of Nutrition, Harvard School of Public Health, 665 Huntington Ave, Boston, Massachusetts 02115, USA
    Circulation 114:160-7. 2006
    ..The burden of CHD that could be avoided through adherence to these modifiable lifestyle factors has not been assessed among middle-aged and older US men, specifically men taking medications for hypertension or hypercholesterolemia...
  44. ncbi Association of the blood/air partition coefficient of 1,3-butadiene with blood lipids and albumin
    Yu-Sheng Lin
    Department of Environmental Health, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Environ Health Perspect 110:165-8. 2002
    ....
  45. ncbi Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study
    Nader Rifai
    Department of Laboratory Medicine, Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Clin Chem 50:1364-71. 2004
    ..This study was designed to examine the ability of baseline Lp(a) concentration and apo(a) size to predict future severe angina pectoris in apparently healthy men...
  46. ncbi Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:183-94; quiz 147, 273-4. 2005
    ..Psychiatrists should address this problem by adopting established strategies for prevention and intervention...
  47. ncbi Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project
    Marc A Pfeffer
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 105:2341-6. 2002
    ..Therapeutic decisions regarding pharmacological therapy should be based on safety and tolerability as well as efficacy data. Clinical trials designed to assess efficacy are often insufficiently powered to generate reliable safety data...
  48. ncbi Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans
    Hannia Campos
    Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Room 1 201, Boston, MA 02115, USA
    Atherosclerosis 181:345-51. 2005
    ..Although small apoB-48 lipoproteins may be atherogenic remnant particles, their very low concentration may diminish their clinical significance...
  49. ncbi The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations
    Frank M Sacks
    Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Cardiol 90:139-43. 2002
  50. ncbi Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat
    Chunyu Zheng
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    J Lipid Res 47:1771-9. 2006
    ..Once in plasma, intestinal and hepatic triglyceride-rich lipoproteins have similar rates of clearance and participate interactively in similar metabolic pathways, with high apoB-48 production inhibiting the clearance of apoB-100...
  51. ncbi Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction
    Edward A Ruiz-Narváez
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Clin Nutr 87:1932-8. 2008
    ..Genetic variation in the insulin response element of the APOC3 promoter is associated with an increased risk of MI...
  52. ncbi Food group sources of nutrients in the dietary patterns of the DASH-Sodium trial
    Pao Hwa Lin
    Department of Medicine, Duke University Medical Center, Durham, NC, USA
    J Am Diet Assoc 103:488-96. 2003
    ..Each of these food groups contributes critical nutrients across various sodium levels. It is important to emphasize all food groups when trying to follow this proven dietary pattern...
  53. ncbi Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial
    Kausik K Ray
    TIMI Study Group, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 46:1405-10. 2005
    ..In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy. Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy...
  54. ncbi Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006
    Alice H Lichtenstein
    Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, USA
    Arterioscler Thromb Vasc Biol 26:2186-91. 2006
  55. ncbi Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions
    Chunyu Zheng
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    J Lipid Res 48:1190-203. 2007
    ....
  56. ncbi Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells
    Akio Kawakami
    Department of Nutrition, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115, USA
    Circulation 114:681-7. 2006
    ..Therefore, apoCIII-rich VLDL may contribute directly to atherogenesis by activating ECs and recruiting monocytes to them...
  57. ncbi High-intensity statin treatment for coronary heart disease
    Frank M Sacks
    JAMA 291:1132-4. 2004
  58. ncbi The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB poly
    Greetje J de Grooth
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Am Coll Cardiol 43:854-7. 2004
    ....
  59. ncbi Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials
    Olga A Iakoubova
    Celera, Inc, Alameda, California 94502, USA
    J Am Coll Cardiol 51:435-43. 2008
    ....
  60. ncbi Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses
    Charles H Hennekens
    Mount Sinai Medical Center Miami Heart Institute, Department of Medicine and Epidemiology and Public Health, University of Miami School of Medicine, Boca Raton, FL 33432, USA
    Arch Intern Med 164:40-4. 2004
    ..Pravastatin has a predominantly delayed antiatherogenic effect, and aspirin has an immediate antiplatelet effect, raising the possibility of additive clinical benefits...
  61. ncbi Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease
    Marcello Tonelli
    Division of Nephrology and Division of Critical Care Medicine, University of Alberta, and Institute of Health Economics, Edmonton, Alberta, Canada
    Circulation 112:171-8. 2005
    ..We performed this analysis to determine whether pravastatin reduced the rate of kidney function loss over approximately 5 years in people with or at high risk for coronary disease...
  62. ncbi Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus
    Sung-Joon Lee
    School of Medicine, Stanford University, Stanford, California, USA
    Am J Cardiol 92:121-4. 2003
    ....
  63. ncbi Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease
    Marcello Tonelli
    University of Alberta, Edmonton, Alberta, Canada
    J Am Soc Nephrol 14:1605-13. 2003
    ..These findings require confirmation by a large randomized trial conducted specifically in people with chronic renal insufficiency...
  64. ncbi Low-density lipoprotein lowering therapy: an analysis of the options
    Frank M Sacks
    J Am Coll Cardiol 40:2135-8. 2002
  65. ncbi Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency
    Marcello Tonelli
    Division of Nephrology and Immunology, University of Alberta, Clinical Sciences Building, Suite 11-108C, 8440 112 Street, Edmonton, Alberta T6B 2B7, Canada
    Ann Intern Med 138:98-104. 2003
    ..Since statins may be underused in this setting, physicians should consider prescribing them for patients with chronic renal insufficiency and known coronary disease...
  66. ncbi A dietary pattern that lowers oxidative stress increases antibodies to oxidized LDL: results from a randomized controlled feeding study
    Edgar R Miller
    Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins Medical Institutions, 2024 East Monument Street, Suite 2 624, Baltimore, MD 21205 2223, USA
    Atherosclerosis 183:175-82. 2005
    ..We tested the hypothesis that consumption of a healthy diet rich in fruits and vegetables and reduced in saturated fat, total fat, and cholesterol will concomitantly reduce oxidative stress and Ab-oxLDL...
  67. ncbi Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke
    Koustubh Ranade
    Pharmaceutical Research Institute, Bristol Myers Squibb, Princeton, NJ 08543 5400, USA
    Stroke 36:2346-50. 2005
    ..We evaluated, in a comprehensive way, all 3 paraoxonase genes for association with stroke observed in the Cholesterol and Recurrent Events (CARE) trial...
  68. ncbi Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS
    Olga A Iakoubova
    Celera Inc, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA
    Arterioscler Thromb Vasc Biol 26:2763-8. 2006
    ..Because the myeloid IgA Fc receptor encoded by FCAR mediates inflammation, we hypothesized that the FCAR Asp92Asn polymorphism is associated with risk of MI and that this risk would be modified by pravastatin...
  69. ncbi Lessons learned from the prospective pravastatin pooling project
    Robert P Byington
    Department of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1063, USA
    Curr Atheroscler Rep 6:366-74. 2004
    ..Pravastatin was shown to safely reduce all-cause mortality, fatal and nonfatal coronary events, and stroke events in patients with a broad range of patient characteristics...
  70. ncbi Effect of pravastatin on cardiovascular events in people with chronic kidney disease
    Marcello Tonelli
    Division of Nephrology, University of Alberta, 7 129 Clinical Science Building, 8440 112 St, Edmonton, Alberta T6G 2G3, Canada
    Circulation 110:1557-63. 2004
    ..The objective of this analysis was to determine whether pravastatin reduced the incidence of cardiovascular events in people with or at high risk for coronary disease and with concomitant moderate CKD...
  71. ncbi Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial
    Lawrence J Appel
    Welch Center for Prevention, Epidemiology and Clinical Research, Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205 2223, USA
    JAMA 294:2455-64. 2005
    ..Reduced intake of saturated fat is widely recommended for prevention of cardiovascular disease. The type of macronutrient that should replace saturated fat remains uncertain...
  72. ncbi Your health in the 21st century. Fine-tuning heart health
    Frank M Sacks
    Newsweek 145:22-3. 2005
  73. ncbi Adherence to statin therapy: why aren't we doing better?
    Frank M Sacks
    Am J Med 113:685-6. 2002
  74. ncbi The effect of ambient temperature and barometric pressure on ambulatory blood pressure variability
    Megan Jehn
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Baltimore, MD 21205-2223, USA
    Am J Hypertens 15:941-5. 2002
    ..CONCLUSIONS: During periods of cold weather, an increase in BP variability may complicate the diagnosis and management of hypertension and may contribute to the high cardiovascular mortality observed in the winter...
  75. ncbi Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association
    Lawrence J Appel
    Hypertension 47:296-308. 2006
    ....
  76. ncbi Dietary phytoestrogens to prevent cardiovascular disease: early promise unfulfilled
    Frank M Sacks
    Circulation 111:385-7. 2005
  77. ncbi Sodium and blood pressure: no data dredging, please!
    Frank M Sacks
    Am J Hypertens 16:614-6. 2003
  78. ncbi Polyunsaturated fatty acids, inflammation, and cardiovascular disease: time to widen our view of the mechanisms
    Frank M Sacks
    J Clin Endocrinol Metab 91:398-400. 2006
  79. ncbi Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial
    Eva Obarzanek
    Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 8136, MSC 7936, Bethesda, MD 20892 7936, USA
    Hypertension 42:459-67. 2003
    ....
  80. ncbi Effect of dietary sodium intake on blood lipids: results from the DASH-sodium trial
    David W Harsha
    Pennington Biomedical Research Center, Baton Rouge, LA, USA
    Hypertension 43:393-8. 2004
    ..There were no significant interactions between the effects of sodium and the DASH diet on serum lipids. In conclusion, changes in dietary sodium intake over the range of 50 to 150 mmol/d did not affect blood lipid concentrations...
  81. ncbi Soy protein, isoflavones, and cardiovascular health: a summary of a statement for professionals from the american heart association nutrition committee
    Frank M Sacks
    Arterioscler Thromb Vasc Biol 26:1689-92. 2006
  82. ncbi A further subgroup analysis of the effects of the DASH diet and three dietary sodium levels on blood pressure: results of the DASH-Sodium Trial
    George A Bray
    Pennington Biomedical Research Center, Baton Rouge, Lousiana, USA
    Am J Cardiol 94:222-7. 2004
    ....
  83. ncbi Acceptability of sodium-reduced research diets, including the Dietary Approaches To Stop Hypertension diet, among adults with prehypertension and stage 1 hypertension
    Njeri Karanja
    Kaiser Permanente Center for Health Research, Portland, OR, USA
    J Am Diet Assoc 107:1530-8. 2007
    ..Examine the acceptability of sodium-reduced research diets...

Research Grants17

  1. Dietary Macronutrients and Weight Loss
    Frank Sacks; Fiscal Year: 2007
    ..The results will be straightforwardly applicable to public health and clinical guidelines for obesity, and will increase our understanding of the biology of obesity and weight loss. ..
  2. Carbohydrate: Amount and Type Affecting Risk for CVD and Diabetes
    Frank M Sacks; Fiscal Year: 2010
    ..We expect that the results will be immediately applicable to public health and clinical guidelines, and will influence nutrition policy. ..
  3. Carbohydrate: Amount and Type Affecting Risk for CVD and Diabetes
    Frank Sacks; Fiscal Year: 2009
    ..We expect that the results will be immediately applicable to public health and clinical guidelines, and will influence nutrition policy. ..
  4. Carbohydrate: Amount and Type Affecting Risk for CVD and Diabetes
    Frank Sacks; Fiscal Year: 2007
    ..We expect that the results will be immediately applicable to public health and clinical guidelines, and will influence nutrition policy. ..
  5. VLDL and LDL Particle Types as CHD Risk Factors
    Frank Sacks; Fiscal Year: 2006
    ..abstract_text> ..
  6. Apo A2, C1 and C2 and Diet in human apoB Metabolism
    Frank Sacks; Fiscal Year: 2005
    ..abstract_text> ..
  7. KINETICS OF HUMAN POSTPRANDIAL LIPOPROTEIN METABOLISM
    Frank Sacks; Fiscal Year: 2001
    ..These studies will increase our understanding of the metabolic pathways that are activated or suppressed postprandially, and could lead to treatments for reducing the development of atherosclerosis. ..
  8. Dietary Fat and HDL Metabolism
    Frank M Sacks; Fiscal Year: 2010
    ..Direct metabolic studies of HDL in humans that trace its metabolism will be conducted at the end of each diet. The goal is to develop a detailed picture of how unsaturated fat raises HDL and protects against cardiovascular disease. ..